GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes

PHILADELPHIA, December 11, 2007 /PRNewswire-FirstCall/ -- The following is GlaxoSmithKline's response to the retrospective analysis by the Institute for Clinical Evaluative Sciences (ICES) titled "Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes".

GSK believes that the ICES retrospective analysis of the Ontario Drug Benefit (ODB) database has significant limitations and generates misleading conclusions regarding acute myocardial infarction and death. These conclusions are inconsistent with a more robust body of evidence from large, long-term, prospective, well-designed clinical studies, including ADOPT and RECORD.

    -- These long-term trials in diabetic patients comparing rosiglitazone to

       other oral anti-diabetic medicines show no increased risk for

       cardiovascular events compared to other commonly used medications,

       other than the well-known risk of congestive heart failure (CHF) with

       thiazolidinedione (TZDs).


    -- RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of

       Glycaemia in Diabetes) was specifically designed to evaluate the

       cardiovascular safety of rosiglitazone, and is therefore the most

       robust data available.  A recently published interim analysis for

       myocardial infarction and death from cardiovascular causes, or from any

       cause, showed no statistically significant difference between

       rosiglitazone in combination with either metformin or sulfonylurea vs.

       the active comparators of metformin plus sulfonylurea.

In addition, the RESULT clinical study specifically examined an elderly diabetic population, ages 59 to 89, in which 43 percent of the patients were greater than 70 years of age, and demonstrated the safety profile of rosiglitazone to be consistent with the control medicine (sulfonylurea).

Importantly, the results of this study do not reproduce what is already known about the risk of CHF in TZD users. TZDs can cause fluid retention which can lead to or exacerbate heart failure. TZDs also have a similar increased risk of CHF. Yet, in this analysis, pioglitazone is not associated with an increased risk of CHF (Adjusted RR of 0.91 (95% CI = 0.52-1.59) whereas rosiglitazone is associated with 2 fold-increased risk of CHF (Adjusted RR = 1.98 and 95% CI=1.44-2.72) compared to oral anti-diabetic combination therapy. This is inconsistent with the product labeling.

Moreover, the authors of this retrospective analysis fail to acknowledge the findings of large epidemiological studies, encompassing over 1.3 million patients with type 2 diabetes, as well as other similar studies presented during the recent FDA Advisory Committee meeting. These studies have investigated whether use of rosiglitazone in the real world setting is associated with an increase in myocardial infarction or coronary revascularization. The majority of these studies show that rosiglitazone is not associated with an increased risk of myocardial infarction compared to other anti-diabetic agents.

GSK cites the following as examples of the limitations of this retrospective analysis:

    -- As the authors state, patients on TZDs in their analysis may represent

       an older, select group of patients with advanced diabetes and therefore

       higher baseline risk for cardiovascular disease.


       -- The ODB database is composed of a select group of patients.

          Rosiglitazone is only prescribed for those patients who fail

          treatment on metformin and sulfonylurea, or for whom sulfonylurea or

          metformin are contraindicated.  The rosiglitazone patients are

          therefore ones with higher baseline risk for cardiovascular disease.

          The use of rosiglitazone in this database does not reflect its use

          among patients in the real world.

       -- Patients prescribed rosiglitazone alone suffered from more chronic

          diseases compared with those prescribed pioglitazone alone;

          therefore they were sicker patients.  However this difference is not

          corrected for in the analysis of the data and in the study

          conclusions.

       -- The TZD monotherapy patient population in the ICES analysis had a

          4-fold higher rate of kidney impairment, which is indicative of

          patients with more progressive type 2 diabetes.


    -- The authors state that the study may have been underpowered to detect

       adverse effects associated with pioglitazone because of the relatively

       small number of persons prescribed pioglitazone alone.  It is stated

       that larger studies are needed to better determine the relative

       effect of each agent on cardiovascular outcomes.


    -- The ICES analysis included insulin therapy within the TZD combination

       group but excluded insulin combinations within the comparison group.

       Insulin is known to be associated with increased CHF and cardiovascular

       risk.  Therefore, this biases the TZD combination group towards

       increased cardiovascular risk relative to the comparison group.  This

       also permits more advanced patients, with poor glycemic control and who

       are at greater risk of cardiovascular complications, to be included in

       the TZD population while excluding them from the control group.

Avandia(R) (rosiglitazone maleate) is a widely studied oral anti-diabetic medicine for the treatment of type 2 diabetes, and importantly, Avandia has been shown to control blood sugar for longer than the most commonly used oral anti-diabetic medicines - up to five years. When used in the appropriate patient, it is an important treatment option for health-care professionals managing the chronic and life threatening disease of diabetes. Across multiple sources of data, there is no consistent or systematic evidence that rosiglitazone increases the risk of myocardial ischemic events or death in comparison to other anti-diabetic agents.

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline on the World Wide Web at www.gsk.com.

Important Safety Information for Avandia(R) (rosiglitazone maleate)

Avandia, along with diet and exercise, helps improve blood sugar control in patients with type 2 diabetes.

Avandia can cause or worsen heart failure. If you have severe heart failure (very poor pumping ability of the heart), you cannot be started on Avandia. Avandia is also not recommended if you have heart failure with symptoms (such as shortness of breath or swelling) even if these symptoms are not severe.

Avandia may increase your risk of other heart problems that occur when there is reduced blood flow to the heart, such as chest pain (angina) or heart attack (myocardial infarction). This risk appeared higher in patients taking medicines called nitrates or insulin. Taking Avandia with insulin or with nitrates is not recommended.

If you have chest pain or a feeling of chest pressure, you should seek immediate medical attention, regardless of what diabetes medicines you are taking.

    If you take Avandia, tell your doctor right away if you:

    -- Have swollen legs or ankles, a rapid increase in weight or difficulty

       breathing, or unusual tiredness

    -- Experience changes in vision

    -- Become pregnant


    Review your medical history and tell your doctor if you:

    -- Have heart failure or other heart problems

    -- Have liver problems or liver disease

    -- Are pregnant or are nursing

Women taking Avandia should know that Avandia may increase the risk of pregnancy.

More fractures have been observed in women taking Avandia.

For more information about Avandia, please see Patient Information. For further information on Avandia, please see full Prescribing Information.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the company's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report 2006.

CONTACT: US Media, Nancy Pekarek, +1-215-751-7709, or Mary Anne Rhyne,+1-919-483-2839; UK Media, Phil Thomson, Alice Hunt, Joss Mathieson, orClaire Brough, +(020) 8047 5502; US Investors, Frank Murdolo,+1-215-751-7002, or Tom Curry, +1-215-751-5419; European Investors, DavidMawdsley, +(020) 8047 5564, or Sally Ferguson, +(020) 8047 5543

Web site: http://www.gsk.com/

Company News On-Call: http://www.prnewswire.com/comp/801350.html /

Ticker Symbol: (NYSE:GSK)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: December 2007

View comments

Hide
(web5)